Top

Published in:

01-04-2013 | RESPIRATORY EPIDEMIOLOGY

Normal spirometry values in healthy elderly: the Rotterdam Study

Authors: Daan Willem Loth, Till Ittermann, Lies Lahousse, Albert Hofman, Hubert Gerardus Maria Leufkens, Guy Gaston Brusselle, Bruno Hugo Stricker

Published in: European Journal of Epidemiology | Issue 4/2013

Abstract

Although many different reference values for spirometry are available from various studies, the elderly are usually underrepresented. Therefore, our objective was to assess reference values in a sample of healthy participants from a prospective population-based cohort study, including a large proportion of elderly. We included spirometry measurements of healthy, never smokers, from the Rotterdam Study and excluded participants with respiratory symptoms or prescriptions for respiratory medication. Age- and height-specific curves for the 5th (lower limit of normal) and the 50th (median) percentile of Forced Expiratory Volume in 1 s (FEV₁), Forced Vital Capacity (FVC), and the ratio (FEV₁/FVC) were calculated by quantile regression models. The group of healthy elderly study subjects consisted of 1,125 individuals, with a mean age of 68 years, ranging from 47 to 96 years of age. Sex stratified equations for the median and the lower limit of normal were calculated adjusted for age and height. In this study, we report age- and height-dependent reference limits for FEV₁, FVC, and FEV₁/FVC in a large population, and prediction equations for the lower limit of normal and median values for a sample containing a large proportion of healthy elderly.

Available only for authorised users

From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) www.goldcopd.org. [cited Accessed December 2010]; Available from: http://www.goldcopd.org.

Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46.PubMedCrossRef

British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the British Thoracic Society. Thorax. 1997;52 Suppl 5(5):S1–28.

Crapo RO. Pulmonary-function testing. N Engl J Med. 1994;331(1):25–30.PubMedCrossRef

Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313(7059):711–5. (discussion 5–6).PubMedCrossRef

Schunemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118(3):656–64.PubMedCrossRef

Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–8.PubMedCrossRef

DeMeo DL, Silverman EK. Genetics of chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2003;24(2):151–60.PubMedCrossRef

Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet. 2010;42(1):45–52.PubMedCrossRef

10.

Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet. 2010;42(1):36–44.PubMedCrossRef

11.

Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet. 2011;43(11):1082–90.PubMedCrossRef

12.

da Silva LF, Saldiva SR, Saldiva PH, Dolhnikoff M, Bandeira Cientifica P. Impaired lung function in individuals chronically exposed to biomass combustion. Environ Res. 2012;112:111–7.PubMedCrossRef

13.

Quanjer PH, Borsboom GJ, Kivastik J, Merkus PJ, Hankinson JL, Houthuijs D, et al. Cross-sectional and longitudinal spirometry in children and adolescents: interpretative strategies. Am J Respir Crit Care Med. 2008;178(12):1262–70.PubMedCrossRef

14.

Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med. 2008;177(3):253–60.PubMedCrossRef

15.

Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999;159(1):179–87.PubMedCrossRef

16.

Kuster SP, Kuster D, Schindler C, Rochat MK, Braun J, Held L, et al. Reference equations for lung function screening of healthy never-smoking adults aged 18–80 years. Eur Respir J. 2008;31(4):860–8.PubMedCrossRef

17.

Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–68.PubMedCrossRef

18.

Stanojevic S, Wade A, Stocks J. Reference values for lung function: past, present and future. Eur Respir J. 2010;36(1):12–9.PubMedCrossRef

19.

Koch B, Schaper C, Ewert R, Volzke H, Obst A, Friedrich N, et al. Lung function reference values in different German populations. Respir Med. 2011;105(3):352–62.PubMedCrossRef

20.

http://lungfunction.org/publishedreferencevalues.html. 2012 [cited 2012 january 6].

21.

Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-year age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.PubMedCrossRef

22.

Quanjer PH, Hall GL, Stanojevic S, Cole TJ, Stocks J. on behalf of the Global Lungs I. Age- and height-based prediction bias in spirometry reference equations. Eur Respir J. 2011.

23.

Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7(4):403–22.PubMedCrossRef

24.

Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011;26(8):657–86.PubMedCrossRef

25.

van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest. 2009;135(2):368–77.PubMedCrossRef

26.

Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.PubMedCrossRef

27.

Koenker R, editor. Quantile regression: Econometric Society Monograph Serie. Cambridge: Cambridge University Press; 2005.

28.

Miller MR, Pincock AC. Predicted values: how should we use them? Thorax. 1988;43(4):265–7.PubMedCrossRef

29.

Royston P, Sauerbrei W. Multivariable model—building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. New York: Wiley; 2008.

Title: Normal spirometry values in healthy elderly: the Rotterdam Study
Authors: Daan Willem Loth
Till Ittermann
Lies Lahousse
Albert Hofman
Hubert Gerardus Maria Leufkens
Guy Gaston Brusselle
Bruno Hugo Stricker
Publication date: 01-04-2013
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 4/2013
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-013-9800-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Normal spirometry values in healthy elderly: the Rotterdam Study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Dietary fibre and cardiovascular disease mortality in the UK Women’s Cohort Study

The role of milk protein in increasing risk of Parkinson’s disease

Screening results for subclinical coronary artery calcification in asymptomatic individuals in relation to a detailed parental history of premature coronary heart disease

Screening, case finding or primary cancer prevention in the developing world?

Time-dependent propensity score and collider-stratification bias: an example of beta2-agonist use and the risk of coronary heart disease

Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort